The correlation between metabolic syndrome and neurocognitive and social cognitive performance of patients with schizophrenia.
Adolescent
Adult
Brief Psychiatric Rating Scale
Cross-Sectional Studies
Female
Humans
Hypoglycemic Agents
/ therapeutic use
Male
Metabolic Syndrome
/ epidemiology
Middle Aged
Neurocognitive Disorders
/ epidemiology
Neuropsychological Tests
Psychiatric Status Rating Scales
Schizophrenia
/ epidemiology
Schizophrenic Psychology
Social Behavior
Young Adult
MCCB
Metabolic syndrome
Neurocognitive
Schizophrenia
Social cognitive
Journal
Psychiatry research
ISSN: 1872-7123
Titre abrégé: Psychiatry Res
Pays: Ireland
ID NLM: 7911385
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
19
02
2019
revised:
17
03
2020
accepted:
23
03
2020
pubmed:
26
4
2020
medline:
4
11
2020
entrez:
26
4
2020
Statut:
ppublish
Résumé
Cognitive impairment is one of the core symptoms of schizophrenia, and patients with schizophrenia are at increased risk of metabolic syndrome (MS). However, the role of MS in cognitive impairment of schizophrenia is not established. This study investigated the correlation between neurocognitive, social cognitive performance and MS with schizophrenia. One hundred and fifty eight (158) schizophrenia patients were divided into 3 groups with ① normal metabolism, ② metabolic disorder (only meeting 1 or 2 MS criteria), and ③ metabolic syndrome (meeting 3 or more MS criteria). MATRICS Consensus Cognitive Battery)MCCB(and the Brief Psychiatric Rating Scale)BPRS(were used to evaluate cognitive performance and clinical symptoms. Blood samples were obtained to detect glucose and lipid metabolic levels. Overall MCCB and subscale T scores in the normal metabolism and metabolic disorder groups were better than in the MS group. After controlling for the confounding factors including age, sex, the usage of hypolipidemic and hypoglycemic drugs, and disease duration, metabolic deficits had effects on the symbol coding and spatial span scores. The results suggest that a defective metabolic state might play a role in neurocognitive performance of schizophrenia patients.
Identifiants
pubmed: 32334274
pii: S0165-1781(19)30444-5
doi: 10.1016/j.psychres.2020.112941
pii:
doi:
Substances chimiques
Hypoglycemic Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
112941Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest There is no conflict of interest in relation to this paper.